Ann: Paradigm AGM Presentation, page-18

Rusty? I got to ask one more of your questions but 'only' to Chris Fullerton, I didn't have the time to ask it of any others...
There should be no need for any cash raise for next year or two was the answer. They have enough for the two Phase 3 Trials (the big one of course is OA, MPS has reduced fees, it will still cost but nothing like OA)...the quarterly cash burn also was incorporated into his answer which he also mentioned before we got interrupted as they were moving on to lunch.

Another point that comes to mind is PR mentioned in the meeting that they may look at 600 patients for OA Phase three as opposed to 500...I have come across in my research somewhere where it mentions that more is better...it results in a better statistical output...if I come across it I will post it as a separate article to give further colour on this one.